🔬 Can ChatGPT Speak Chemistry? The progress of Large Language Models (LLMs) like ChatGPT has been remarkable in many fields. But so far their success in generative chemistry has been limited—they often struggle even to produce valid molecules. Through experimentation, we’ve found that surprisingly small changes in how you ask LLMs about chemistry can make a big difference in the quality of the output. For example, by simply switching from SMILES to IUPAC notation, we reduced invalid molecules generated by LLMs by over 90%. Curious about how a small change in representation can have such a big impact? Dive into the details in our latest blog: https://lnkd.in/giCGGqh5 #GenerativeChemistry #DrugDiscovery #LLMs #MachineLearning #AI #MedicinalChemistry
About us
Inductive Bio brings the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
- Website
-
https://inductive.bio
External link for Inductive Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Inductive Bio
-
Ankit Mahadevia
Biotech Entrepreneur, Board Member, Author
-
Paul Ornstein
President at Apollo Drug Discovery Consulting, LLC Medicinal Chemistry Consulting, 3rd Party Due Diligence, Expert Witness
-
Cailen DSa
Coach for Startups, Founders & Employees | First GTM @ 6 Unicorns | Building the Silicon Sands Community in San Diego
-
Andrew Larsen, PhD
VP of Partnerships at Inductive Bio
Updates
-
Building intuitive, genuinely helpful tools for medicinal chemists to make more informed decisions is central to Inductive's mission. Sprints are a core part of how we make that happen - thanks to Upstarts for going deep with the Character Capital team on the Sprint process and featuring how we’ve used them at Inductive to focus our business on what matters most to our customers.
I went hands on for today Upstarts Media newsletter, trying out a new startup process called a Foundation Sprint first-hand 👀 Designers Jake Knapp and John Zeratsky have helped hundreds of founders to prototype products. Their VC firm Character Capital has quietly backed ~50 startups out of a previously-unreported $52M fund. So when they offered Upstarts a chance to test out their newest process, detailed in their book 'Click' out today, I jumped. Condensing a two-day process into 3.5 hours, I got a taste of what startup founders who work with Knapp and Zeratsky experience. Then I spoke to their partner Eli Blee-Goldman and entrepreneurs who have worked with them, like Inductive Bio CEO Josh Haimson and stealth founders Mahmoud Arram and Ram Kumar Rengaswamy about how such sprints make them useful investors for the ecosystem. Would you try a Design Sprint or Foundation Sprint? Have you seen value from similar processes? Check out today's story with no paywall, courtesy of our launch partner Brex, and let us know what you think!
-
We're happy to support the Computational Medicinal Chemistry School as a sponsor! Proud to be part of an initiative that’s empowering the next generation of computational chemists.
We are happy to welcome Inductive Bio as a Silver Sponsor (https://lnkd.in/eihjyHZj)! The Computational Medicinal Chemistry School is designed not only for graduate students and postdocs, but also for early-career professionals in industry and those looking to integrate more computational tools into their workflows. If you have any junior computational chemists on your team or medicinal chemist/structural biologists who are looking to pivot into more computational roles, consider suggesting that they apply here https://lnkd.in/et2pm_G9
-
Heading to ACS Spring? Don’t miss Inductive Bio's CEO & Co-founder, Josh Haimson, discussing the latest in AI and drug discovery at two sessions this Sunday and Monday!
The rapid rise of AI in drug discovery brings both the opportunity to discover better therapies for patients faster and the challenges of sifting reality from hype, choosing the right tool for the right program at the right stage, and adapting the drug discovery process to integrate a rapidly evolving set of technologies. How can small biotechs harness these advances to stay competitive with fewer resources? What role will AI play in the future of medicinal chemistry? At ACS Spring 2025, our CEO & Co-founder, Josh Haimson, will dive into these questions and more, exploring how AI is transforming the landscape of drug discovery over 2 sessions: 📅 Sunday, March 23 🎤 Unlocking a New Era: How AI is Transforming Drug Discovery and Development, moderated by Maria-Jesus Blanco 📅 Monday, March 24 🎤 Competing with Goliaths: A Pre-Competitive ADMET ML Consortium Interested in meeting at ACS? Book a demo here: https://lnkd.in/gCHdxZbF #ACSMEDI
-
The rapid rise of AI in drug discovery brings both the opportunity to discover better therapies for patients faster and the challenges of sifting reality from hype, choosing the right tool for the right program at the right stage, and adapting the drug discovery process to integrate a rapidly evolving set of technologies. How can small biotechs harness these advances to stay competitive with fewer resources? What role will AI play in the future of medicinal chemistry? At ACS Spring 2025, our CEO & Co-founder, Josh Haimson, will dive into these questions and more, exploring how AI is transforming the landscape of drug discovery over 2 sessions: 📅 Sunday, March 23 🎤 Unlocking a New Era: How AI is Transforming Drug Discovery and Development, moderated by Maria-Jesus Blanco 📅 Monday, March 24 🎤 Competing with Goliaths: A Pre-Competitive ADMET ML Consortium Interested in meeting at ACS? Book a demo here: https://lnkd.in/gCHdxZbF #ACSMEDI
-
🚨 Did you miss this? Large Language Models (LLMs) have made huge strides across many fields, but their applications in generative chemistry are still evolving. Our blog explores a key insight: simply switching the input notation from SMILES to IUPAC can reduce invalid molecules by over 90%. Catch up on the details here: https://lnkd.in/giCGGqh5 #GenerativeChemistry #DrugDiscovery #LLMs #MachineLearning #AI #MedicinalChemistry
-
We were excited to see Inductive Bio's blog highlighted in Air Street Capital's and Nathan Benaich’s State of AI Report! The report provides a comprehensive overview of the latest in AI for 2024, spanning research, industry advancements, politics, and safety. Explore the full State of AI Report here: https://www.stateof.ai/ Check out our featured Alpha Fold 3 blog here: https://lnkd.in/eEtx8UWN
-
Small molecule optimization is complex, difficult, and expensive. At the Lux Capital AI Summit, Josh Haimson shared how Inductive Bio is transforming this process by combining unique data with cutting-edge ML models to enhance the quality and effectiveness of small molecule drug discovery. Thank you to Lux Capital and all the attendees today!
-
-
Thank you to Elizabeth Joshi (Eli Lilly and Company), Maria-Jesus Blanco (Atavistik Bio), Katerina L., and David Kombo (Sanofi) for the great discussion on the current and potential future applications of ML in drug discovery yesterday! #ACSFall2024
-
-
Congratulations again to Inductive advisor Wendy Young for being inducted into the ACS Division of Medicinal Chemistry Hall of Fame tonight 🎉 We are grateful for your mentorship and support!
-